Access all of the content
It was lovely to speak with Dr Beatriz Mateos (Universidad de Alcalá, Madrid, Spain) about the findings from her research into the impact of tenofovir on the severity of COVID-19 infection in those with chronic hepatitis B.
Her presentation entitled ‘Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients’ was given at EASL ILC 2021, 23-26 June.
- What was the rationale for investigating antiviral treatments, such as tenofovir and entecavir, in the treatment of COVID-19 infection for those with chronic hepatitis B? (0:23)
- Could you briefly summarise the aims of your study, the methods used and the analysis performed? (1:00)
- What were the key clinical findings from the research? (2:23)
- Based on these findings, could tenofovir be providing a protective effect from severe COVID-19 symptoms and what could the clinical impact of these findings be? (3:09)
Disclosures: Dr Beatriz Mateos has nothing to disclose in relation to this video interview
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In COVID-19
Jeffrey Strich: Phase 2 Trial Results Investigating Fostamatinib for the treatment of COVID-19
It was a great pleasure to meet with Jeffrey Strich (National Institutes of Health Clinical Center, Bethesda, MD, USA) to discuss the findings from a recent phase 2 study investigating fostamatinib for the treatment of hospitalized adults with COVID-19. Useful Resources: Published data available here: Fostamatinib for the treatment of hospitalized adults with COVID-19 A […]
Evangelos Giamarellos-Bourboulis: Phase 3 SAVE-MORE Study Results Investigating Anakinra in the Treatment of Severe COVID-19
It was a great pleasure to meet with Prof. Evangelos Giamarellos-Bourboulis (Attikon University Hospital, Athens, Greece) to discuss phase 3 SAVE-MORE study assessing the effect of anakinra for the treatment of patients with COVID-19 pneumonia. Useful Resources: Publication available to access here: https://www.nature.com/articles/s41591-021-01499-z Questions: Could you give us a brief overview of the role of […]
Rifaat Safadi, EASL ILC 2021: Impact of Liver Disease on SARS-CoV-2 Vaccine Response
It was a pleasure to speak with Prof. Rifaat Safadi (Hadassah University Hospital, Ein Kerem, Jerusalem) about the impact of advanced chronic liver disease on the efficacy of the Pfizer and Moderna mRNA SARS-CoV-2 vaccines. His abstract entitled ‘Elderly with advanced liver fibrosis had lower response to Pfizer’s SARS-CoV-2 vaccine response’ was presented at EASL […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!